Oral ALZ-801/valiltramiprosate and its active agent tramiprosate have shown promising efficacy in APOE4 carriers in clinical trials [26,29], and oral ALZ-801/valiltramiprosate is currently being evaluated in the APOLLOE4 Phase 3 trial in APOE4/4 homozygotes with early AD. This evidence concerns the gene APOE and Alzheimer disease.